NCT00976222

Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: University Hospital Muenster · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).

Detailed description

Pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD) have been excluded from practically all study populations of ranibizumab studies so far. PED represents a special entity in AMD. As yet, no standard treatment has been established for this disease.The stimuli that induce PED are not very well known, but there is evidence suggesting that angiogenic factors such as vascular endothelial growth factor (VEGF) also play a role in the pathogenesis. Ranibizumab is an anti-VEGF antibody fragment that blocks VEGF activity in patients with neovascular AMD.

Conditions

• Pigment Epithelial Detachment

Interventions

Type	Name	Description
DRUG	intravitreal injection with ranibizumab	0.5 mg in 0.05 ml, monthly, 12 months

Timeline

• Start date: 2008-12-01
• Primary completion: 2014-12-01
• Completion: 2015-12-01
• First posted: 2009-09-14
• Last updated: 2017-09-29

Locations

2 sites across 1 country: Germany